Gastric Cancer Clinical Trial
Official title:
Fluorescence Image-Guided Lymphadenectomy Using Indocyanine Green and Near Infrared Technology in Robotic Gastrectomy
Gastric cancer is a worldwide challenge due to its spread, even epidemic in some areas, and
the high mortality rates. Lymphadenectomy is considered the fundamental step during radical
gastrectomy. In recent years, some researchers have tried to find a way to improve the
surgical identification of the lymphatic drainage routes and lymph node stations. This new
surgical frontier is the so called "navigation surgery". Among the different reported
solutions, lately, the indocyanine green (ICG) has drawn attention. It is a fluorescence dye,
that can be detected in the near infrared spectral band (NIR). The development of specific
fluorescence imaging devices has allowed surgeons to visualize tumors, vascular and lymphatic
structures. The Da Vinci Xi robotic system has an integrated imaging technology that has been
used in colo-rectal and hepato-biliary surgery. However, up to date, the combined use of
fluorescence imaging and robotic technology has not been evaluated during lymphadenectomy in
gastric cancer.
The general design of the present study is to evaluate the role of fluorescence imaging
during robotic lymphadenectomy for gastric cancer.
Background Gastric cancer is the fourth most widespread cancer in the world and is
characterized by high mortality rates [1, 2]. A multidisciplinary context, in which surgery
plays the main role, is essential to offer the best therapeutic strategy. Lymph node
involvement in gastric cancer is present in 2-18% when the depth of the tumor invasion is
limited to the mucosal or submucosal layer, but rises to 50% when the tumor involves the
subserosa [3]. Lymphadenectomy is a fundamental surgical phase that must guarantee the
oncological radicality and allow an appropriate tumor staging. Although it is among the most
relevant factors influencing long-term survival, its extension and standardization is still
the subject of much debate. The two latest editions of the Japanese Gastric Cancer
Association (JGCA) guidelines [4] recommend a dissection on different levels (D1, D1 +, D2)
depending on the type of gastrectomy and the clinical stage of the tumor. In recent years,
some researchers have tried to apply the concept of "sentinel lymph node" to gastric cancer
[5-7]. Although some do not consider that terminology the appropriate one in the context of
gastric cancer, because of the multidirectional gastric lymphatic flows, several studies have
highlighted interesting aspects, such as: limiting an extensive lymphatic dissection when not
necessary, identifying the drainage routes outside the standard anatomical planes, possible
assistance in minimally invasive procedures [8]. Most of the experiences in lymph nodes
mapping were performed with a radio-isotope (Tc99m) associated or not with the intraoperative
use of vital dyes (Blue dye). More recently, the properties of the ICG have been studied.
This is a fluorescence dye, that can be detected in the NIR [9, 10]. The development of
imaging tools using "NIR / ICG" technology is therefore an innovative approach for
visualizing tumors, vascular structures, lymphatic channels, and lymph nodes [11]. Some
advantages of the ICG are: reduced toxicity, absence of radioactivity, low cost, safe
administration both intravenously and endoscopically through the submucosa or subserosa,
protein binding without changing molecular structures, macrophages interaction at the lymph
node level. Devices for fluorescence imaging are currently available in both open and
minimally invasive surgery.
In this field, robotic surgery has been becoming of great interest thanks to the
manufacturing of new instruments which, compared to laparoscopy, allow to improve manual
skills and gentleness in challenging movements [12]. The Da Vinci Xi robotic system has also
produced an innovative imaging technology for ICG visualization made up with a laser source
integrated in the robotic camera (Firefly). The surgeon at the console has therefore a 3-D
vision that can switch to the fluorescence mode without the need to change the camera. Few
clinical experiences have been reported to date [12]. Published articles refer to assistance
in colo-rectal and hepato-biliary surgery for vessels or biliary structures visualization,
while its use during lymph node dissection for gastric cancer has not yet been the subject of
study protocols.
Hypothesis: fluorescence imaging during lymphadenectomy in gastric cancer can significantly
improve the quality of the dissection through a better visualization of anatomical planes and
allow tailored dissections. Moreover, the tumor status in the fluorescent nodes could predict
the nodes status in the overall specimen with high accuracy rate.
Methods General study design: the overall objective is verifying the feasibility and the role
of a lymphadenectomy assisted by fluorescence imaging during robotic gastrectomy.
Two levels of investigation are planned:
- to detect the possible advantages of a fluorescence-guided surgery ("Navigation
Surgery");
- to evaluate the possibility of considering the lymph nodes labeled by the ICG as
predictive of the state of tumor diffusion ("Targeted Surgery") Type of study:
Interventional study.
Specific aims:
1. To verify the ability of the procedure to highlight the main tumor lymphatic drainage
pathways.
2. To validate the concept of Navigation Surgery in gastric surgery by comparing the group
of the experimental procedure with a control group undergoing the same type of surgery
but not assisted by fluorescence.
3. To find a correlation between the nodes marked by the ICG and the remaining nodes
removed during the procedure.
4. To identify the characteristics of those patients in whom the ICG can effectively
discriminate the type of lymphadenectomy to be performed.
Data collection: the following information will be collected for each patient.
- General variables: demographic, histopathological, intra and post-operative features,
complications. - Specific variables: total number of lymph nodes retrieved (LNs), Fluorescent
lymph nodes (FLNs), metastatic LNs, LNs by station, FLNs outside the standard dissection
plane, FLNs status (positive or negative for tumor), non-fluorescent LNs status
Definitions and subdivision of patients:
- True positive patients: patients in which FLNs positive for tumor are detected when LNs
positive for tumor are found in the analysis of the surgical specimen.
- False positive patients: patients in which FLNs positive for tumor are detected when LNs
negative for tumor are found in the analysis of the surgical specimen.
- True negative patients: patients in which FLNs negative for tumor are detected when LNs
negative for tumor are found in the analysis of the surgical specimen.
- False negative patients: patients in which FLNs negative for tumor are detected when LNs
positive for tumor are found in the analysis of the surgical specimen.
Sample size: considering the volume of patients included in published studies available in
the literature on the use of fluorescence imaging and adding that the present project is the
first to describe the use of robotic technology with fluorescence assistance in gastric
cancer, a total of 20 patients will be enrolled for the experimental procedure. An additional
sample including 20 patients will be the control group, based on the same eligibility
criteria. The total sample of patients planned for the present study is therefore of 40
subjects.
Statistical analysis: SPSS v23 will be used to perform data analysis. The dichotomous
variables will be expressed as numbers and percentages, while the continuous variables as
mean and standard deviation, or median and IQR (minimum and maximum values). For the
comparison with the control group, the continuous variables will be analyzed with the T test
for independent samples and a value of P <0.05 will be considered statistically significant.
Impact on clinical practice and healthcare system: this project can pave the way for a new
concept of lymphadenectomy in gastric cancer involving minimally invasive surgery. Patients
could benefit from a more tailored approach to their disease.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |